Close Menu

More articles about Cancer

The German molecular diagnostics firm brought in revenues of €4.3 million ($5.8 million) for the year as it launched its first test.

Preparing for commercialization of its LungExpress Dx test, the company boosted R&D spending and trimmed general costs.

The collaborators will use Asuragen's microRNA technologies to identify potential biomarkers for use in pancreatic cancer diagnostic tests.

At the Network Biology 2.0 conference, speakers underscored the degree to which the understanding of cancer is being empowered by molecular characterization projects and is accompanied by the desire to select the right populations for clinical trials.

While RXi continues to bill itself as an RNAi drug developer, a company official indicated this week that the firm may expand its focus into the miRNA field as it works to meet its goal of defining its areas of therapeutic interest by the end of the second quarter.

American researchers reported today that they have sequenced the genomes of a primary breast tumor, brain metastasis, and matched normal tissue from an African-American woman with basal-like breast cancer as well as a xenograft sample derived from primary tumor tissue.

An Agendia official said that the company has provided "new, corrected MammaPrint reports" for all of the physicians who received faulty results and has also implemented internal quality-control measures to guard against a similar issue in the future.

The Australian firm has acquired, among other assets, the BrevaGen breast cancer risk test, which it expects to launch in the second half of this year.

"We're in discussions with pharmaceutical companies, diagnostic companies, and governments to put together programs to start testing thousands of serum samples."

Pairings: Apr 14, 2010


Jan Groen

Their results, detailed this month in PLoS ONE, suggest that this approach — sequencing, at a high depth, chromosomal regions identified by linkage tests — may be a good method for identifying genes in hereditary disease.

The partners will assess potential biomarkers, beyond KRAS, of response to cancer drug cetuximab (Erbitux).

Synlab has started offering Epi proColon, Epigenomics' PCR-based blood test for early detection of colorectal cancer, through 55 German sites in its network. In addition, Epigenomics recently raised €33.1 million ($44.2 million) through a combined private and public share offering.

The company said that the move will allow patients to use its miRNA test without having to undergo more invasive procedures to obtain tumor samples.

Ahead of a cost-effectiveness appraisal by UK's NICE, AstraZeneca is paying for EGFR mutation testing for non-small cell lung cancer patients to determine if they will benefit from treatment with Iressa. The genetic testing program is part of a patient access scheme the company has agreed to with the National Health Service to provide more granularity about the cost and value of the treatment.

Decode is hoping to incorporate the recently discovered SNP on chromosome 4p16 into a multi-gene panel test for UBC, according to Decode's Kari Stefansson.

The exclusive distribution agreement with Palex Medical, a distributor of medical diagnostic services and devices in Europe, will bring Oncotype DX to breast cancer patients in Spain and Portugal.

New Releases: Apr 7, 2010


Agendia's BluePrint

Scientists from the company and JHU will use a $340,000 NCI grant to test metabolomic pathways as indicators of lung cancer therapeutic resistance.

A US District Court's ruling that Myriad's BRCA patents are invalid will definitely be appealed in the Federal Circuit, and will probably reach the Supreme Court, according to legal experts.


A new analysis suggests warming, not the arrival of humans, led to the extinction of the woolly rhinoceros thousands of years ago, the Economist reports.

Chinese health officials uncovered SARS-CoV-2 viral RNA on imported frozen food, but the New York Times reports catching COVID-19 that way would be unlikely.

The UK has ordered 60 million coronavirus vaccine doses from Novavax and 30 million doses from Janssen, according to the Guardian.

In Science this week: machine learning model predicts whether ion channel mutations will cause disease, and more.